RevOpsis Therapeutics, a pioneering biopharmaceutical firm at the forefront of developing advanced ophthalmic therapies, has named Ronil Patel as its new Chief Business Officer. Patel brings over 15 years of extensive experience in biotechnology and global business development to his role, effective immediately.
In his new capacity, Patel will steer RevOpsis’ global strategy and spearhead business development initiatives. His impressive background includes pivotal roles in drug development, strategic decision-making in research and development, and the implementation of rapid market entry strategies.
“We are delighted to welcome Ronil Patel to the RevOpsis team,” remarked Ram Bhandari, interim CEO of RevOpsis. “His profound expertise in the healthcare sector, particularly in ophthalmology, combined with his strategic acumen, will be invaluable as we advance our lead asset, RO-104, and expand our portfolio of product candidates. Ronil’s leadership will be pivotal in driving our corporate strategy, enhancing business development efforts, and achieving operational excellence.”
Patel currently serves as a strategic advisor at Collage Venture Partners and previously held the role of Chief Business Officer at Ocuphire Pharma, a prominent publicly traded biotechnology company specializing in ophthalmology. His career highlights include leading business development at Point Guard Partners and Oculos Clinical Research (now iuvo Bioscience), where he contributed significantly to securing substantial funding and finalizing high-profile licensing and exit deals.
“The scientific innovation driving RevOpsis, particularly the RevMod platform and its lead asset, RO-104, addressing critical needs in the retina market, attracted me to this opportunity,” said Patel. “The company’s vision, coupled with a strong commitment to patient care, was compelling in my decision to join. My primary objective is to position RevOpsis for accelerated growth as we progress our product candidates through the drug development pipeline. Additionally, I aim to expand partnerships with pharmaceutical collaborators and investors to amplify RevOpsis’ impact.”
Patel emphasized the current challenges and opportunities in the ophthalmic industry, noting funding as a significant hurdle. He highlighted RevOpsis as one of the few private companies successfully securing funding to advance RO-104 through critical milestones. Addressing sustainability and treatment durability in retinal vascular diseases, Patel underscored RevOpsis’ potential to revolutionize patient care through multispecific biologics for ocular applications.
Looking ahead, Patel envisions RevOpsis as a global leader in multispecific antibodies, beginning with advancements in retinal disease treatment. His strategic roadmap includes leveraging existing capabilities, forging strategic alliances, and securing vendor partnerships to accelerate the company’s progression into human clinical trials.
“My vision for RevOpsis is centered on maximizing the ‘plug-and-play’ capabilities of the RevMod platform,” Patel added. “We have a talented team poised to advance our product candidates, and our goal is to collaborate with partners possessing the expertise, resources, and shared commitment to bring these candidates to fruition.”
